Publicacións en colaboración con investigadores/as de Fundación Hipercolesterolemia Familiar (32)

2024

  1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study

    American Journal of Preventive Cardiology, Vol. 17

  2. Characteristics of Coronary Atherosclerosis Related to Plaque Burden Regression During Treatment With Alirocumab: The ARCHITECT Study

    Circulation. Cardiovascular imaging, Vol. 17, Núm. 1, pp. e016206

  3. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study

    Atherosclerosis, Vol. 393

  4. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 643-652

2023

  1. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study

    Circulation, Vol. 147, Núm. 19, pp. 1436-1443

  2. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 320-328

2022

  1. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort

    European Journal of Preventive Cardiology, Vol. 29, Núm. 5, pp. 795-801

  2. Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?

    Current Atherosclerosis Reports, Vol. 24, Núm. 6, pp. 427-434

2021

  1. Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 31, Núm. 7, pp. 2014-2022

  2. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study

    Atherosclerosis, Vol. 317, pp. 52-58

  3. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience

    Journal of Clinical Lipidology, Vol. 15, Núm. 4, pp. 584-592

  4. High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolaemia patients

    Cardiovascular Research, Vol. 117, Núm. 1, pp. 109-122

  5. Lipoprotein(a), LDL-cholesterol, and hypertension: Predictors of the need for aortic valve replacement in familial hypercholesterolaemia

    European Heart Journal, Vol. 42, Núm. 22, pp. 2201-2211

  6. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

    JACC: Cardiovascular Imaging, Vol. 14, Núm. 12, pp. 2414-2424

2020

  1. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

  2. Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 40, Núm. 10, pp. 2508-2515

2019

  1. Adults with familial hypercholesterolaemia have healthier dietary and lifestyle habits compared with their non-affected relatives: The SAFEHEART study

    Public Health Nutrition, Vol. 22, Núm. 8, pp. 1433-1443

  2. Association of dietary components with dyslipidemia and low-grade inflammation biomarkers in adults with heterozygous familial hypercholesterolemia from different countries

    European Journal of Clinical Nutrition, Vol. 73, Núm. 12, pp. 1622-1625

  3. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study

    Journal of Clinical Lipidology, Vol. 13, Núm. 6, pp. 989-996

  4. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia

    Atherosclerosis, Vol. 286, pp. 40-45